A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity

Bellier, Bertrand; Saura, Alicia; Luján, Lucas A.; Molina, Cecilia R.; Luján, Hugo Daniel; Klatzmann, David

dc.creator	Bellier, Bertrand
dc.creator	Saura, Alicia
dc.creator	Luján, Lucas A.
dc.creator	Molina, Cecilia R.
dc.creator	Luján, Hugo Daniel
dc.creator	Klatzmann, David
dc.date	2022-02-25
dc.date.accessioned	2022-09-21T22:03:32Z
dc.date.available	2022-09-21T22:03:32Z
dc.identifier	http://pa.bibdigital.ucc.edu.ar/3253/1/A_Saura_Luj%C3%A1n_Luj%C3%A1n.pdf
dc.identifier.uri	https://hdl.handle.net/20.500.12032/46107
dc.description	An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia, affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.
dc.description	Fil: Bellier, Bertrand. Sorbonne Université. INSERM. UMRS 959. Immunology-Immunopathology-Immunotherapy; Francia
dc.description	Fil: Saura, Alicia. Universidad Católica de Córdoba. CONICET. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE); Argentina
dc.description	Fil: Saura, Alicia. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentina
dc.description	Fil: Luján, Lucas A. Universidad Católica de Córdoba. CONICET. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE); Argentina
dc.description	Fil: Luján, Lucas A. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentina
dc.description	Fil: Molina, Cecilia R. Universidad Católica de Córdoba. CONICET. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE); Argentina
dc.description	Fil: Molina, Cecilia R. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentina
dc.description	Fil: Luján, Hugo Daniel. Universidad Católica de Córdoba. CONICET. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE); Argentina
dc.description	Fil: Luján, Hugo Daniel. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentina
dc.description	Fil: Klatzmann, David. Universidad Católica de Córdoba. CONICET. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE); Argentina
dc.description	Fil: Klatzmann, David. AP-HP, Hôpital Pitié-Salpêtrière. Clinical Investigation Center for Biotherapies (CIC-BTi) and Immunology-Inflammation-Infectiology and Dermatology Department (3iD); Francia
dc.format	application/pdf
dc.language	spa
dc.publisher	Frontiers Media S.A.
dc.relation	http://pa.bibdigital.ucc.edu.ar/3253/
dc.relation	https://www.frontiersin.org/articles/10.3389/fimmu.2022.837443/full
dc.relation	info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.3389/fimmu.2022.837443
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.source	Bellier, Bertrand, Saura, Alicia ORCID: https://orcid.org/0000-0003-1537-506X <https://orcid.org/0000-0003-1537-506X>, Luján, Lucas A. ORCID: https://orcid.org/0000-0003-4235-4301 <https://orcid.org/0000-0003-4235-4301>, Molina, Cecilia R., Luján, Hugo Daniel ORCID: https://orcid.org/0000-0002-3797-8315 <https://orcid.org/0000-0002-3797-8315> and Klatzmann, David (2022) A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity. Frontiers in Immunology, 13. ISSN 1664-3224
dc.subject	Q Ciencia (General)
dc.subject	QR180 Inmunología
dc.subject	QR355 Virología
dc.title	A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
dc.type	info:eu-repo/semantics/article
dc.type	info:ar-repo/semantics/artículo

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Documentos - UCC

Mostrar el registro sencillo del ítem